Most domestic medical AI-related stocks failed to escape weakness, with gains and losses clearly diverging by stock. Out of 30 stocks, 27 declined, while only a handful rose.

EngenBio Posts Largest Drop... Lunit and Vuno Also Weak

The stock with the largest decline this session was EngenBio, which closed at 1,729 won, down 476 won (21.59%). Acryl fell 2,240 won (13.63%) to 14,190 won, and Spear dropped 2,130 won (12.56%) to 14,830 won, both posting double-digit declines.

Thears (-9.87%), Threebillion (-9.42%), Parobio (-8.69%), and Neurophet (-7.81%) also recorded declines in the 7–10% range. Industry bellwethers Lunit (-4.79%), Vuno (-6.42%), Labgenomics (-2.07%), and Noeul (-5.93%) likewise failed to escape the broader weakness.

SelvasAI Surges Alone... Trading Volume Overwhelming

Meanwhile, a small number of stocks trended upward. JLK rose 10 won (0.19%) to 5,150 won, and SisunAI gained 150 won (5.84%) to close at 2,720 won.

The most notable stock was SelvasAI. It traded at 9,010 won, surging 950 won (11.79%), with a trading volume of 12,559,820 shares — overwhelmingly the highest among the stocks included in the table.

Rally Catalyst: Naver-NVIDIA Investment News

SelvasAI's surge is analyzed to be linked more to improved investment sentiment toward the broader domestic AI industry than to internal factors within the medical AI sector. On the 27th, Naver announced it would pursue a third-party allotment capital increase worth $1 billion targeting NVIDIA. Through this investment, NVIDIA will acquire a 4.5% stake in Naver.

This marks Naver's first third-party allotment capital increase since its KOSPI listing in 2008, and upon completion of payment, NVIDIA will become Naver's third-largest shareholder after the National Pension Service and BlackRock.

After this news broke, SelvasAI rose in tandem with NAVER, MaeumAI, and others, reflecting the trend of improving AI investment sentiment. SelvasAI is categorized not only under medical AI but also as an AI chatbot and software theme stock, suggesting that expectations for expanded domestic AI infrastructure investment drove the rally rather than medical AI-specific catalysts.

Cause of 27-Stock Plunge Remains Unclear

Meanwhile, no disclosures or news directly explaining the simultaneous plunge of the remaining 27 stocks have been identified.

However, concerns had already been raised within the industry about Lunit and Vuno, the representative medical AI stocks. Lunit faced financial risks, while Vuno's business pace and cash flow were cited as challenges due to failures in obtaining overseas regulatory approvals. Some analyses suggested that Lunit needed to achieve profitability through capital reinforcement, while Vuno needed to rebuild its growth narrative through reattempting U.S. approval and redesigning its NTAP.

However, whether these individual risks are directly linked to this decline requires further confirmation. Additionally, medical AI-related stocks have historically shown sector-wide weakness when foreign selling intensified, raising the possibility that this plunge was also driven by supply-demand outflow rather than any specific catalyst. That said, this possibility also lacks confirmed evidence.

Key Variables to Monitor Going Forward

The future watchpoints highlighted by experts are as follows:

• Distinguishing Supply-Demand vs. Risk: It is necessary to determine whether this decline stems from supply-demand outflow due to net selling by foreigners and institutions, or from risks related to individual company disclosures, clinical trials, or regulatory approvals.
• Sustainability of SelvasAI's Strength: Whether it is a one-off thematic reaction or whether the rally will spread broadly to domestic AI infrastructure stocks following the Naver-NVIDIA investment is a key question.
• Bellwether Disclosures: Future disclosures from Lunit, Vuno, and others (capital reinforcement, overseas approval progress) will be critical variables in gauging stock price direction.

At present, there is insufficient basis to determine whether this plunge is a temporary correction or a trend.

[※ This article was written based on intraday market prices and does not recommend buying or selling any specific stock. Stock prices may fluctuate during trading hours, so please verify the latest disclosures and market prices before actual trading. This article was written with AI assistance.]